Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States

Authors:

Abstract
No abstract available
Funding Information
  • Amgen Inc

This publication has 27 references indexed in Scilit: